GeoVax Labs appoints Shahin Behroyan as director and Tyler O’Brien as interim CEO
GeoVax Labs (GOVX) appointed Shahin Behroyan as a director and Tyler O’Brien as interim CEO, effective November 5 and 8, 2026. Behroyan fills a vacancy from five resignations. O’Brien also becomes Chairman of the Board. Behroyan will receive standard non-employee director compensation.
How this was made

The 30-second read
Why it matters
The leadership change is a routine corporate action with limited immediate price impact, but it provides a fresh data point for analysts monitoring the company's governance and strategic direction.
Market read
Primary corporate filing; modest relevance for traders focused on biotech micro‑caps and governance events.
What to watch
Potential hidden strategic shifts or partnership talks that may accompany the leadership change.
Background
The article summarizes a recent SEC 8‑K filing by GeoVax Labs, a Nasdaq‑listed biotech company, detailing its board and executive appointments.
Ticker impact
GeoVax Labs filed an 8‑K announcing Shahin Behroyan as director and Tyler O’Brien as interim CEO, effective early November 2026.
potential modest pressure as investors assess the leadership change
The filing is a primary disclosure of a new interim CEO and director, but the change is routine and does not involve material financial terms.
Market effects
Minimal impact on the broader biotech sector; leadership changes are common and unlikely to shift sector dynamics.
Limited to U.S. biotech investors; no regional ripple effect expected.
Low global relevance; the news is specific to GeoVax Labs.
Counterpoint
If the new interim CEO accelerates clinical milestones, the stock could rally despite typical caution.
Key entities
- companyGeoVax Labs
Nasdaq‑listed biotech firm (ticker GOVX) reporting executive appointments.
- personShahin Behroyan
Appointed as director effective November 5, 2026.
- personTyler O’Brien
Appointed as interim CEO effective November 8, 2026.
